


THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method for the treatment, amelioration and/or prophylaxis of a neurological condition which comprises the administration of an effective amount of a compound of formula

5 I:



I

in which

10 R^1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted acyl, optionally substituted aryl, optionally substituted heterocyclyl, an antioxidant or a targeting moiety;


R^2 is H; optionally substituted alkyl; optionally substituted alkenyl; optionally substituted aryl; optionally substituted heterocyclyl; optionally substituted alkoxy; an antioxidant; a targeting moiety; COR^6 or CSR^6 in which R^6 is H, optionally substituted alkyl, optionally substituted alkenyl, hydroxy, optionally substituted aryl, optionally substituted heterocyclyl, an antioxidant, a targeting moiety, OR^7 , SR^7 or NR^7R^8 in which R^7 and R^8 are either the same or different and selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heterocyclyl; CN; $(CH_2)_nNR^9R^{10}$, $HCNOR^9$ or $HCNNR^9R^{10}$ in which R^9 and R^{10} are either the same or different and selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heterocyclyl and n is 1 to 4; OR^{11} , SR^{11} or $NR^{11}R^{12}$ in which R^{11} and R^{12} are either the same or different and selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heterocyclyl or together form optionally substituted heterocyclyl; or $SO_2NR^{13}R^{14}$ in which R^{13} and R^{14} are either the same or different and selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heterocyclyl; and

R^3 , R^4 , R^5 , R and R' are either the same or different and selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, optionally substituted acyl, hydroxy, optionally substituted amino, optionally substituted thio,

optionally substituted sulphonyl, optionally substituted sulphinyl, optionally substituted sulphonylamino, halo, SO₃H, amine, CN, CF₃, optionally substituted aryl, optionally substituted heterocyclyl, an antioxidant or a targeting moiety,

salts, hydrates, solvates, derivatives, pro-drugs, tautomers and/or isomers thereof with the provisos that:

- (a) when R^1 to R^3 , R and R' are H, then R^4 is not Cl or I and R^5 is not I;
(b) when R^1 to R^3 , R , R' and R^5 are H, then R^4 is not CHO, CHOHCCl_3 ,



- (c) when R^1, R^5, R' and R are H, R^2 is CO_2H and R^3 is OH, then R^4 is not bromo, methyl, phenyl, hydroxymethyl or trifluoromethyl;
- (d) when R^1, R^4, R^5 and R are H, R^2 is CO_2H and R^3 is OH, then R' is not bromo, iodo, methyl, phenyl, propyl, phenethyl, heptyl, benzylaminomethyl, 3-aminopropyl, 3-hydroxypropyl, 4-methoxyphenyl, 3-methylphenyl, 4-chlorophenyl, 3,4-dichlorophenyl, pyridin-3-yl, furo-2-yl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 3-chlorophenyl, 2-methoxyphenyl or piperidin-2-yl;
- (e) when R^1, R^4, R and R' are H, R^2 is CO_2H and R^3 is OH, then R^5 is not phenyl, 3-hydroxypropyl, phenethyl, 3-aminoprop-1-yl or hex-1-yl;
- (f) when R^1, R^4, R' and R^5 are H, R^2 is CO_2H and R^3 is OH, then R is not N-

morpholinomethyl, bromo or phenyl;

(g) when R^1 , R and R' are H, R^2 is CO_2H and R^3 is OH, then R^4 and R^5 are not chloro;

(h) when R^1 , R^4 and R' are H, R^2 is CO_2H and R^3 is OH, then R and R^5 are not bromo;

(i) when R^1 , R, R' and R^5 are H, R^2 is CO_2Me and R^3 is OH, then R^4 is not hydroxymethyl, phenyl or bromo;

(j) when R^1 , R, R^4 and R^5 are H, R^2 is CO_2Me and R^3 is OH, then R' is not 4-methoxyphenyl, 3-methylphenyl, pyridin-3-yl, benzyl, bromo, 4-chlorophenyl, 3,4-dichlorophenyl, 3-hydroxypropyl or 3-tert-butoxycarbonylaminopropyl;

(k) when R^1 , R, R^4 and R' are H, R^2 is CO_2Me and R^3 is OH, then R^5 is not phenyl or 3-tert-butoxycarbonylaminoprop-1-yl;

(l) when R^1 , R, R^4 , R' and R^5 are H and R^2 is CO_2Me , then R^3 is not toluene-4-sulphonylamino, piperazin-1-yl, morpholin-1-yl, piperidin-1-yl, 4-methylpiperazin-1-yl, 3-benzoylaminoprop-1-yl, phenethyl, 3-tert-butoxycarbonylaminopropyl, 3-hydroxypropyl, amino or hex-1-yl;

(m) when R^1 , R^4 , R' and R^5 are H, R^2 is CO_2Na and R^3 is OH, then R is not phenyl;

(n) when R^1 , R, R^4 , R' and R^5 are H and R^2 is CO_2H , then R^3 is not phenyl, 4-chlorophenyl, phenethyl, 3-hydroxypropyl, amino, morpholin-1-yl, piperidin-1-yl, 4-methylpiperazin-1-yl, toluene-4-sulphonylamino, 3-benzoylaminoprop-1-yl, aminoprop-1-ynyl, hex-1-yl, 5-hydroxypent-1-yl, piperazin-1-yl or 2-(1-piperazinyl)pyrimidinyl;

(o) when R^1 , R' and R are H, R^2 is CO_2Me and R^3 is OH, then R^4 and R^5 are not chloro;

(p) when R^1 , R^4 , R' and R^5 are H, R^2 is CO_2Me and R^3 is OH, then R is not bromo;

(q) when R^1 , R' and R^4 are H, R^2 is CO_2Me and R^3 is OH, then R and R^5 are not bromo;

(r) when R^1 , R, R^3 , R' and R^5 are H and R^2 is CO_2H , then R^4 is not phenyl, 4-chlorophenyl or phenylethyl;


(s) when R^1 , R^5 , R' , R^4 , R^3 and R are H, then R^2 is not 2H-tetrazol-1-yl;

(t) when R^1 , R^5 , R^4 and R are H, R^2 is CO_2H and R^3 is OH, then R' is not 3,5-dichlorophenyl or 4-fluorophenyl; and

(u) at least one of R^1 to R^5 , R and R' is other than H, to a subject in need thereof.

2. A method according to claim 1, in which the compound of the formula I is either:

(i) Formula Ia



Ia


5 in which:

R, R¹ and R³ are as defined in claim 1; and

R²ₐ is H; optionally substituted C₁-₆ alkyl; optionally substituted C₁-₆ alkenyl; optionally substituted aryl; optionally substituted heterocyclyl; an antioxidant; a targeting moiety; COR⁶ₐ or CSR⁶ₐ in which R⁶ₐ is H, optionally substituted C₁-₆ alkyl, optionally substituted C₂-₆ alkenyl, hydroxy, optionally substituted aryl, optionally substituted heterocyclyl or OR⁷ₐ, SR⁷ₐ or NR⁷ₐR⁸ₐ in which R⁷ₐ and R⁸ₐ are either the same or different and selected from H, optionally substituted C₁-₆ alkyl, optionally substituted C₂-₆ alkenyl, optionally substituted aryl or optionally substituted heterocyclyl; CN; CH₂NR⁹ₐR¹⁰ₐ, HCNOR⁹ₐ or HCNNR⁹ₐR¹⁰ₐ in which R⁹ₐ and R¹⁰ₐ are either the same or different and selected from H, optionally substituted C₁-₆ alkyl, optionally substituted C₂-₆ alkenyl, optionally substituted aryl or optionally substituted heterocyclyl; OR¹¹ₐ, SR¹¹ₐ or NR¹¹ₐR¹²ₐ in which R¹¹ₐ and R¹²ₐ are either the same or different and selected from H, optionally substituted C₁-₆ alkyl, optionally substituted C₂-₆ alkenyl, optionally substituted aryl or optionally substituted heterocyclyl or together form optionally substituted heterocyclyl; or SO₂NR¹³ₐR¹⁴ₐ in which R¹³ₐ and R¹⁴ₐ are either the same or different and selected from H or optionally substituted C₁-₆ alkyl, optionally substituted C₂-₆ alkenyl, optionally substituted aryl or optionally substituted heterocyclyl; or

- 120 -

(ii) Formula Ib



Ib


in which:

R¹, R', R, R² and R³ are as defined in claim 1;

5 R⁴ᵇ and R⁵ᵇ are either the same or different and selected from H; optionally substituted C₁₋₆ alkyl; optionally substituted C₂₋₆ alkenyl; halo; CN; CF₃; optionally substituted aryl; optionally substituted heterocyclyl; an antioxidant; a targeting moiety; SO₃H; SO₂NR¹³_aR¹⁴_a in which R¹³_a and R¹⁴_a are as defined in formula Ia above; or OR¹⁵_b, SR¹⁵_b, SO₂R¹⁵_b, CONR¹⁵_bR¹⁶_b or NR¹⁵_bR¹⁶_b in which R¹⁵_b and R¹⁶_b are either the same or different and
10 selected from H, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₁₋₆ acyl, optionally substituted aryl or optionally substituted heterocyclyl, including provisos (a) to (c), (e), (g), (h), (I), (k), (o), (q), (r), and (u) as defined in claim 1.

15 3. A method according to claim 2, in which the compound of formula Ia is as follows:

o Formula IIa




IIa

in which:

20 R¹ is as defined in claim 1 or claim 2; and
R²' is optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl,

optionally substituted aryl or optionally substituted heterocyclyl;

◦ Formula IIIa



IIIa


5 in which:

R^1 and R^3 are as defined in claim 1 or claim 2; and

$R_a^{6'}$ is optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, hydroxy, $OR_a^{7'}$, $SR_a^{7'}$, $N_2R_a^{7'}R_a^{8'}$, or $NR_a^{7'}R_a^{8'}$ in which $R_a^{7'}$ and $R_a^{8'}$ are either the same or different and selected from H, optionally substituted C_{1-6} alkyl, optionally substituted aryl or optionally substituted heterocyclyl;

10

◦ Formula IVa



IVa

in which:


R^1 is as defined in claim 1 or claim 2; and

$R_a^{2'}$ is CN; $CH_2NR_a^{9'}R_a^{10'}$, $HCNOR_a^{9'}$ or $HCNNR_a^{9'}R_a^{10'}$ in which $R_a^{9'}$ and $R_a^{10'}$ are either the same or different and selected from H, optionally substituted C_{1-6} alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heterocyclyl;

15

- 122 -

◦ Formula Va




Va

in which:

- 5 R¹ is as defined in claim 1 or claim 2; and
 R¹¹'ₐ and R¹²'ₐ are either the same or different and selected from H, optionally
 substituted C₁-₆ alkyl, optionally substituted C₂-₆ alkenyl, optionally substituted aryl and
 optionally substituted heterocyclyl or together form optionally substituted heterocyclyl; or

10 ◦ Formula VIa



VIa


in which:

- R¹ is as defined in claim 1 or claim 2; and
 R¹³'ₐ and R¹⁴'ₐ are either the same or different and selected from H, optionally
 15 substituted C₁-₆ alkyl, optionally substituted C₂-₆ alkenyl, optionally substituted aryl or
 optionally substituted heterocyclyl.

- 123 -

4. A method according to claim 2, in which the compound of the formula Ib is as follows:

o Formula IIb




IIb

5 in which:

R¹, R', R, R² and R³ are as defined in claim 1 or claim 2; and

R⁴ᵇ and R⁵ᵇ are as defined in formula Ib above provided that at least one is halo, including provisos (a), (c), (g), (h), (i), (o), (q) and (u) defined in claim 1;

10 o Formula IIIb



IIIb

15 in which:


R¹ is as defined in claim 1 or claim 2;

R⁴ᵇ is H or halo; and

R⁵ᵇ is optionally substituted aryl or optionally substituted heterocyclyl;

- 124 -

• Formula IVb




IVb

in which:

R¹ is as defined in claim 1 or claim 2;

5 R'' is C₁₋₆ alkoxy, halo, C₁₋₆ alkyl, C₂₋₆ alkenyl or C₁₋₆ haloalkyl; and
R^{5b} is H or halo;

• Formula Vb




Vb

in which

10 R¹ is as defined in claim 1 or claim 2; and
R'' is as defined in formula IVb above; or

- 125 -

o Formula VIb



VIb

in which:

R² to R⁵, R and R' are as defined in claim 1 or claim 2; and

5 R^{1b} is optionally substituted C₁₋₆ alkyl, optionally substituted aryl, optionally substituted aryl acyl, C₁₋₆ alkyl acyl or optionally substituted heterocyclyl.


5. A method according to any one of claims 1, 2 or 4, in which the compound of formula I is a compound of formula Ib or IIb in which R^{4b} and R^{5b} or R^{4b'} and R^{5b'} are both halo.

10 6. A method according to claim 5, in which the halo is chloro.

7. A method according to any one of claims 1, 2 or 4 to 6, in which at least one of R², R, R³ and R' is optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocyclyl, CH₂NR⁹R¹⁰ in which R⁹ and R¹⁰ are as defined in claim 1, COR⁶ in which R⁶ is NR⁷R⁸ in which R⁷ and R⁸ are as defined in claim 1 or NR¹¹R¹² in which R¹¹ and

15 R¹² are as defined in claim 1.

8. A method for the treatment, amelioration and/or prophylaxis of a neurological condition which comprises the administration of an effective amount of a compound of formula Ic:



Ic

in which

R^1 , R^2 , R^3 , R and R' are as defined in claim 1; and

at least one of R^4_c and R^5_c is halo and the other is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, optionally substituted acyl, hydroxy, optionally substituted amino, optionally substituted thio, optionally substituted sulphonyl, optionally substituted sulphinyl, optionally substituted sulphonylamino, SO_3H , amine, CN, CF_3 , optionally substituted aryl, optionally substituted heterocyclyl, an antioxidant and a targeting moiety,

salts, hydrates, solvates, derivatives, pro-drugs, tautomers and/or isomers thereof with the provisos that:

(a) when R^1 to R^3 , R and R' are H, then R^4_c is not chloro or iodo and R^5_c is not iodo;

(b) when R^1 , R^5_c , R' and R are H, R^2 is CO_2H and R^3 is OH, then R^4_c is not bromo;

(c) when R^1 , R and R' are H, R^2 is CO_2H and R^3 is OH, then R^4_c and R^5_c are not chloro;


(d) when R^1 , R^4_c and R' are H, R^2 is CO_2H or CO_2Me and R^3 is OH, then R and R^5_c are not bromo;

(e) when R^1 , R , R' and R^5_c are H, R^2 is CO_2Me and R^3 is OH, then R^4_c is not bromo; and

(f) when R^1 , R and R' are H, R^2 is CO_2Me and R^3 is OH, then R^4_c and R^5_c are not chloro,

to a subject in need thereof.

9. A method for the treatment, amelioration and/or prophylaxis of a neurological condition which comprises the administration of an effective amount of a compound of formula IIc:



in which

- 127 -


R^2 , R , R' , R^4_c and R^5_c are as defined in claim 8; and

$R^{3'}$ is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, optionally substituted acyl, optionally substituted amino, optionally substituted thio, optionally substituted sulphonyl, optionally substituted sulphinyl, optionally substituted sulphonylamino, halo, SO_3H , amine, CN, CF_3 , optionally substituted aryl, optionally substituted heterocyclyl, an antioxidant or a targeting moiety,

with the proviso that at least one of R , R^2 and $R^{3'}$ is other than H, salts, hydrates, solvates, derivatives, prodrugs, tautomers and/or isomers thereof, to a subject in need thereof.

10. A method according to claim 8 or claim 9, in which the compound of the formula IIc is as follows:

○ Formula IIIc




IIIc

in which:

R^1 is as defined in claim 1 and R^4_c is as defined in claim 8 ; and R^{5_c} is optionally substituted aryl or optionally substituted heterocyclyl;

- 128 -

○ Formula IVc




IVc

in which:

5 R^1 is as defined in claim 1, R^5_c is as defined in claim 8 and R'' is as defined in claim 4; and

○ Formula Vc



Vc

in which:

10 R^2 , R^3 , R and R' are as defined in claim 1, R^4_c and R^5_c are as defined in claim 8 and R^{1_b} is as defined in claim 4.

11. A method according to any one of claims 8 to 10, in which R^4_c and R^5_c are both halo.

15


12. A method according to claim 11, in which the halo is chloro.

- 129 -


13. A method according to any one of claims 8 to 12, in which at least one of R^2 , R^3 and R' is optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocyclyl, $CH_2NR^9R^{10}$ in which R^9 and R^{10} are as defined in claim 1, COR^6 in which R^6 is
5 NR^7R^8 in which R^7 and R^8 are as defined in claim 1 or $NR^{11}R^{12}$ in which R^{11} and R^{12} are as defined in claim 1.

14. A method according to any one of claims 1, 2 or 4 to 13, in which the compound
is as follows:


10




PBT 1038




PBT 1050




PBT 1052



PBT 1033



PBT 1056



PBT 1051

15. A method according to any one of claims 1 to 14, in which the neurological

- 130 -

condition is a neurodegenerative disorder.

16. A method according to claim 15, in which the neurodegenerative disorder is neurodegenerative amyloidosis.

17. A method according to claim 15 or claim 16, in which the neurodegenerative disorder is sporadic or familial Alzheimer's disease, amyotrophic lateral sclerosis, cataract, Parkinson's disease, Creutzfeldt-Jacob disease and its new variant associated with "mad cow" disease, Huntington's disease, dementia with Lewy body formation, multiple system atrophy, Hallerboden-Spatz disease, diffuse Lewy body disease, fatal familial insomnia, Gertsman Straussler Sheinker disease or hereditary cerebral haemorrhage with amyloidosis-Dutch type.

18. A method according to claim 17, in which the neurodegenerative disorder is Parkinson's disease.

19. A method according to any one of claims 15 to 17, in which the neurodegenerative disorder is an A β -related condition.

20. A method according to claim 19, in which the A β -related condition is Alzheimer's disease or dementia associated with Down syndrome or one of several forms of autosomal dominant forms of familial Alzheimer's disease.

21. A method according to any one of the preceding claims which slows, reduces or arrests the cognitive decline of the subject.

22. A method according to any one of the preceding claims, which further comprises separate, sequential or simultaneous administration of another medicament.

23. A method according to claim 22, in which the other medicament is an inhibitor of the acetylcholinesterase active site, an antioxidant, an anti-inflammatory agent or an oestrogenic agent.

24. A method according to any one of the preceding claims, in which the compound is administered orally, topically or parenterally.

25. Use of the compound as defined in any one of claims 1 to 14, in the manufacture of a medicament for the treatment, amelioration and/or prophylaxis of a neurological condition.

- 131 -

26. Use of a compound as defined in any one of claims 1 to 14 for the treatment, amelioration and/or prophylaxis of a neurological condition.

5 27. A compound as defined in any one of claims 1 to 14 for use in the treatment, amelioration and/or prophylaxis of a neurological condition.

28. Use of the compound as defined in any one of claims 1 to 14, as a pharmaceutical.

10 29. Use according to claim 28, in which the pharmaceutical is a neurotherapeutic or neuroprotective agent.


15 30. Use according to claim 28 or claim 29, in which the pharmaceutical is an anti-amyloidogenic agent.

31. A pharmaceutical or veterinary composition comprising the compound as defined in any one of claims 1 to 14 and a pharmaceutically or veterinarily acceptable carrier.

20 32. A composition according to claim 31 which further comprises another medicament.

25 33. A composition according to claim 32, in which the other medicament is an inhibitor of the acetylcholinesterase active site, an antioxidant, an anti-inflammatory agent or an oestrogenic agent.


34. A compound as defined in any one of claims 1 to 7, with the provisos that:

30 (a) when R^1 and R^3 to R^5 , R and R' are H, then R^2 is not H, methyl, 




- 132 -

CO₂H, CN, CONCH₂CO₂H, COCH₃, CH₂NH₂, CNOH, (pyrid-2-yl), 2-hydroxyphenyl,
CHNHNH₂, NH-(pyrid-2-yl),




(b) when R¹ and R⁴ to R⁷ are H, then R³ is not OH and R² is not CO₂H;

10 (c) when R¹ to R³, R⁶ and R⁷ are H, then (i) when R⁵ is I, R⁴ is not Cl, SO₃H or I; (ii) when R⁵ is H, R⁴ is not SO₃H, NH₂ or Cl; (iii) R⁴ and R⁵ are both not Cl, Br or CH₃; and (iv) when R² to R⁷ are H, then R¹ is not



20 (d) when R¹ to R³, R and R' are H, then R⁴ is not Cl or I and R⁵ is not I;

(e) when R¹ to R³, R, R' and R⁵ are H, then R⁴ is not CHO, CHOHCCL₃,



(f) when R^1 , R^5 , R' and R are H, R^2 is CO_2H and R^3 is OH, then R^4 is not bromo, methyl, phenyl, hydroxymethyl or trifluoromethyl;

(g) when R^1 , R^4 , R^5 and R are H, R^2 is CO_2H and R^3 is OH, then R' is not bromo, iodo, methyl, phenyl, propyl, phenethyl, heptyl, benzylaminomethyl, 3-aminopropyl, 3-hydroxypropyl, 4-methoxyphenyl, 3-methylphenyl, 4-chlorophenyl, 3,4-dichlorophenyl, pyridin-3-yl, furo-2-yl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 3-chlorophenyl, 2-methoxyphenyl or piperidin-2-yl;

(h) when R^1 , R^4 , R and R' are H, R^2 is CO_2H and R^3 is OH, then R^5 is not phenyl, 3-hydroxypropyl, phenethyl, 3-aminoprop-1-yl or hex-1-yl;

(i) when R^1 , R^4 , R' and R^5 are H, R^2 is CO_2H and R^3 is OH, then R is not N-morpholinomethyl, bromo or phenyl;

(j) when R^1 , R and R' are H, R^2 is CO_2H and R^3 is OH, then R^4 and R^5 are not chloro;

(k) when R^1 , R^4 and R' are H, R^2 is CO_2H and R^3 is OH, then R and R^5 are not bromo;

(l) when R^1 , R , R' and R^5 are H, R^2 is CO_2Me and R^3 is OH, then R^4 is not hydroxymethyl, phenyl or bromo;

(m) when R^1 , R , R^4 and R^5 are H, R^2 is CO_2Me and R^3 is OH, then R' is not 4-methoxyphenyl, 3-methylphenyl, pyridin-3-yl, benzyl, bromo, 4-chlorophenyl, 3,4-dichlorophenyl, 3-hydroxypropyl or 3-tert-butoxycarbonylaminopropyl;

(n) when R^1 , R , R^4 and R' are H, R^2 is CO_2Me and R^3 is OH, then R^5 is not phenyl or 3-tert-butoxycarbonylaminoprop-1-yl;

(o) when R^1 , R , R^4 , R' and R^5 are H and R^2 is CO_2Me , then R^3 is not toluene-4-sulphonylamino, piperazin-1-yl, morpholin-1-yl, piperidin-1-yl, 4-methylpiperazin-1-yl, 3-benzoylaminoprop-1-yl, phenethyl, 3-tert-butoxycarbonylaminopropyl, 3-hydroxypropyl, amino or hex-1-yl;

(p) when R^1 , R^4 , R' and R^5 are H, R^2 is CO_2Na and R^3 is OH, then R is not phenyl;

(q) when R^1 , R , R^4 , R' and R^5 are H and R^2 is CO_2H , then R^3 is not phenyl, 4-chlorophenyl, phenethyl, 3-hydroxypropyl, amino, morpholin-1-yl, piperidin-1-yl, 4-methylpiperazin-1-yl, toluene-4-sulphonylamino, 3-benzoylaminoprop-1-yl, aminoprop-1-ynyl, hex-1-yl, 5-hydroxypent-1-yl, piperazin-1-yl or 2-(1-piperazinyl)pyrimidinyl;

(r) when R^1 , R' and R are H, R^2 is CO_2Me and R^3 is OH, then R^4 and R^5 are not chloro;

(s) when R^1 , R^4 , R' and R^5 are H, R^2 is CO_2Me and R^3 is OH, then R is not bromo;

(t) when R^1 , R' and R^4 are H, R^2 is CO_2Me and R^3 is OH, then R and R^5 are not bromo;

(u) when R^1 , R , R^3 , R' and R^5 are H and R^2 is CO_2H , then R^4 is not phenyl, 4-

chlorophenyl or phenylethyl;

(v) when R^1, R^5, R', R^4, R^3 and R are H, then R^2 is not 2H-tetrazol-1-yl;

(w) when R^1, R^5, R^4 and R are H, R^2 is CO_2H and R^3 is OH, then R' is not 3,5-

dichlorophenyl or 4-fluorophenyl; and

5 (x) at least one of R^1 to R^5, R and R' is other than H;

(y) when R^1 to R^3, R^5, R' and R are H, then R^4 is not chloro, NH_2 or SO_3H ; and

(z) when R^1, R^3 to R^5, R and R' are H, then R^2 is not CH_3 .

35. A compound of formula Ic as defined in claim 8, with the additional provisos

10 that:

(g) when R^1 to R^3, R and R' are H, then R^4_c and R^5_c are both not chloro or bromo;

and

(h) when R^1 to R^3, R^5_c, R and R' are H, then R^4_c is not chloro.

15 36. A compound of formula IIc as defined in claim 9.







37. A compound according to claim 35 or claim 36 in which R^4_c and R^5_c are both halo.

20 38. A compound according to claim 37, in which the halo is chloro.

39. A compound according to any one of claims 35 to 38, in which at least one of R^2, R, R^3 and R' is optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocyclyl, $CH_2NR^9R^{10}$ in which R^9 and R^{10} are as defined in claim 1, COR^6 in which R^6 is
25 NR^7R^8 in which R^7 and R^8 are as defined in claim 1 or $NR^{11}R^{12}$ in which R^{11} and R^{12} are as defined in claim 1.

- 135 -

40. A compound according to any one of claims 34 to 39, which is as follows:



- 5
41. A process for the preparation of the compound as defined in any one of claims 34 to 40 as described herein.